Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$9.26MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steve N. Slilaty
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 50
- Beta
- 1.35
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.77
Financials
Revenue
$9.26M+10061.1%Net Income
$-1.56MEBITDA
$-1.53MFree Cash Flow
$-912.8KEPS (diluted)
$-1.15Shares Outstanding (diluted)
1.37M+416157.3%Operating Expenses
$3.96MCash & Debt
$13.75MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $36.31M | $-5.98M | $-14.40 |
| 2024 | $34.87M | $-5.13M | $-73.20 |
| 2023 | $24.09M | $-4.51M | $-3513.60 |
| 2022 | $4.35M | $-26.74M | $-35236.40 |
| 2021 | $228.4K | $-12.44M | $-97743.20 |
| 2020 | $71.4K | $-2.78M | $-32148.90 |
| 2019 | $21.1K | $-1.66M | $-188669.40 |
| 2018 | $447.2K | $-2.16M | $-1420.00 |
| 2017 | $0.00 | $-1.04M | $-238.40 |
| 2016 | $0.00 | $-3.50M | $-1646.30 |
| 2015 | $1.7K | $-1.65M | $-16529080.00 |
| 2014 | $0.00 | $-1.93M | $-5261.70 |
| 2013 | $0.00 | $-2.49M | $-8271.90 |
| 2012 | $0.00 | $-708.0K | $-2756.80 |
Valuation
SBFMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
95-5.00%Social Signal Score
Mentions (6)
- Newsaccessnewswire.com·6d ago·Neutral
…million of potential aggregate gross proceeds upon the exercise of warrants FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $…
View source ↗ - Newsaccessnewswire.com·7d ago·Neutral
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, …
View source ↗ - Newszacks.com·21d ago·Positive
Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know Sunshine Biopharma, Inc. (SBFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsaccessnewswire.com·29d ago·Neutral
…bioavailability and preferential lung enrichment across multiple species FORT LAUDERDALE, FL / ACCESS Newswire / September 16, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in oncology and antivirals, is pleased to announce that it has advanced its lead Coronavirus drug candidate into IND-enabling studies. The Company had previously published laboratory results on its l…
View source ↗ - Newsaccessnewswire.com·45d ago·Positive
Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.
View source ↗ - Newsaccessnewswire.com·50d ago·Neutral
…accine in NSCLC with the goal of converting "cold" tumors into "hot" tumors FORT LAUDERDALE, FL / ACCESS Newswire / August 26, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today provided an update and outlined next plans for its oncology project, the K1.1 mRNA lipid nanoparticle (LNP) program. The gene encoding the K1.1 mRNA is a tu…
View source ↗
Earnings
Thu, Nov 12(in 4 weeks)
Consensus estimate $-0.17 per share
Typical surprise -28.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.15 vs $-1.20beat
- Wed, May 13$-2.50 vs $-2.50beat
- Fri, Apr 3$-3.00 vs $-2.70miss
- Thu, Nov 13$-1.90 vs $-1.30miss
- Tue, Aug 12$-3.90 vs $-1.10miss
- Mon, Mar 31$-10.10 vs $0.10miss
Estimates and results for SBFM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SBFM officers and directors.
- Bought
- $165k
- Sold
- $130k
6 trades
1 trade
- Slilaty Steve N.boughtdirector, 10 percent owner, officer: Chief Executive Officer·100,000 @ $0.10·$10k·Mar 4, 2024·filing
- Slilaty Steve N.bought
- Sebaaly Camillebought
- Sebaaly Camillebought
- Slilaty Steve N.bought
- Slilaty Steve N.boughtdirector, 10 percent owner, officer: Chief Executive Officer·500,000 @ $0.10·$50k·May 27, 2015·filing
- Slilaty Steve N.solddirector, 10 percent owner, officer: Chief Executive Officer·2,591,500 @ $0.05·$130k·Sep 4, 2012·filing
70 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Roger Williamshouse · TX25 · disclosed Jun 12, 2024 (713d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.